Detailed Narrative
Aggressive Capacity Expansion to Capture China-Plus-One
Sai Life is significantly stepping up its investment cycle, planning a ₹700 crore capex for FY26, a sharp increase from the ₹408 crore spent in FY25. This investment is aimed at adding 30% manufacturing capacity and building out capabilities in new modalities like Peptides, ADCs, and Oligonucleotides. Management believes this front-loading of capex is necessary to win long-term diversification contracts from global pharma companies looking for alternatives to Chinese suppliers.
Margin Expansion Trajectory and Operating Leverage
The company achieved a 25% EBITDA margin in FY25, up from 20% in FY24, driven by better capacity utilization and a shift toward higher-value CRO services. Management reiterated its long-term guidance to reach 28-30% margins within the next 2-3 years. While Q4 margins were slightly dampened by a ₹34 crore one-time📎 provision, the underlying operating leverage remains strong as the business scales.
Strategic Shift Toward Large Pharma and Integrated Services
Sai Life is successfully deepening its penetration into 'Big Pharma,' with 18 of the top 25 global companies now as customers. The revenue mix in the CRO segment from large pharma has increased from 30% to 37% over the past year. This shift provides more stability compared to the volatile biotech sector, which management expects to remain flat or 'level off' for the next two years.
Financial De-leveraging Post-IPO
A key highlight of the fiscal year was the repayment of ₹720 crores in debt using IPO proceeds. This move has significantly strengthened the balance sheet and is expected to result in lower interest costs starting in FY26. Despite the aggressive ₹700 crore capex plan for next year, the company intends to fund it through a mix of internal accruals, remaining IPO funds, and modest debt, maintaining a disciplined capital structure.
Emerging Modalities: Peptides and ADCs
The launch of a dedicated Peptide Research Center in Hyderabad marks a pivot toward complex therapeutics. Management noted that 80-90% of current customer pipelines involve conjugation products like ADCs and peptides. By investing ₹50-60 crores specifically in these new modalities, Sai Life is positioning itself to follow the 'molecule' from discovery through to commercial manufacturing in the next generation of drug development.